EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Biohit Oyj B (BIOBV) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Biohit Oyj B €2.71, price €2.33, upside +16.3%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · FI · ISIN FI0009005482

BO Some data Sep 23, 2026

Biohit Oyj B

BIOBV · HE

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value €2.71 · Undervalued (+16%)
!Quality 51/100
!Expensive Growth (revenue 5y +17.1 %/yr)
✓Solidly profitable · 17.4% net margin (TTM)
!Low debt · negative free cash flow
✓Ranks above peers (10/13)
✓Wide moat 70/100
!Evidence only medium, so the estimate is less certain
Watch Biohit Oyj B for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€3.96 €1.09 Fair Value €2.71 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range €1.09 – €3.96 · fair‑value band €2.20 – €3.30 · the €2.33 price screens below the €2.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Biohit Oyj B in your weekly email

Every Wednesday you see whether Biohit Oyj B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide.

Show more

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practitioners in interpreting GastroPanel test results; and GP Reader NT for the quantitative determination of various analytes in human samples. It also provides BIOHIT active B12 (HoloTC) test, BIOHIT total 25OH vitamin D test, and BIOHIT Calprotectin; BIOHIT ColonView quick test for detection of fecal occult blood (FOB) in stool samples; BIOHIT Celiac quick test, a qualitative in vitro immunochromatographic test aiding in diagnosis of celiac disease; BIOHIT H. pylori UFT300 and H.pylori tests for the diagnosis of H,pylori infection; lactose intolerance quick test kit; and Gluten Immunogenic Peptides test. In addition, it offers Acetium acetaldehyde binding products, such as the Acetium lozenge to help quit smoking and Acetium capsule for the protection of the stomach. Further, the company provides monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. Additionally, it offers BIOHIT FAEX sample system for the collection and handling of stool samples. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.

Stock analysis

Biohit Oyj B (BIOBV) currently trades at €2.33, while our model-based Fair Value estimate is €2.71, implying the stock looks roughly 14.0% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of €3.45 per share, and 10 of the 15 models we run sit above the €2.33 price.

Bear case: the Asset-Based group reads lowest at €0.6600, and 5 of the 15 models stay below the price. Evidence for this calculation is medium.

Scenario range: €2.20 (bear) to €3.30 (bull), the price of €2.33 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Biohit Oyj B reported revenue of €15.7M in FY2025 versus €9.4M in FY2021, a compound +13.8%/yr. Reported net income was €2.7M in FY2025.

Key figures

Market cap €40.8M · P/E ratio 12.9 · P/S ratio 2.22 · EPS (TTM) €0.1802 · Net margin 17.2% · Return on equity 20.2% · Return on assets (EBIT) 8.4% · Operating margin 22.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 16%, BIOBV screens cheaper than that median.

Fair Value models

Bear €2.20 Fair Value €2.71 Bull €3.30
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.1322 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings €2.14 €3.14 €4.62 75
EPV €1.95 €2.22 €2.46 72
ROIC Compounder €2.06 €2.51 €3.01 71
All 15 models by family
DCF Models
Owner Earnings €2.14 €3.14 €4.62 75
Earnings-Based
Graham-Dodd €1.21 €3.78 €5.02 62
Lynch FV €0.8200 €1.18 €1.53 58
PEG = 1.0 €0.8200 €1.18 €1.53 55
EPV €1.95 €2.22 €2.46 72
Multiples
P/E Multiple €2.93 €3.91 €4.89 61
P/S Multiple €2.27 €3.02 €3.78 56
P/B Multiple €2.27 €3.02 €3.78 53
EV/EBIT €2.91 €3.81 €4.70 65
EV/EBITDA €2.78 €3.63 €4.49 66
EV/Revenue €2.14 €2.96 €3.78 53
Asset-Based
NCAV (Graham) €0.4900 €0.6600 €0.9800 53
Economic Profit
Residual Income €1.12 €1.47 €4.72 57
ROIC Compounder €2.06 €2.51 €3.01 71
Growth Earnings
Growth-Adj P/E €2.42 €3.45 €4.49 66

Open the full fair value analysis →

Notify me when BIOBV reaches fair value

Put BIOBV on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 51/100

Of which business quality 50 · Market factors (momentum, volatility) 38

Profitability 66
Margins and returns on capital today
Quality Growth 22
Are margins and returns improving?
Cashflow 1
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 30
Disciplined investing over empire-building
Low Volatility 66
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 13
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Start year 2020 (pandemic). Over 10 years: +10.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.5%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+29.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−45% → 20%

Watch BIOBV, get fair value alerts →

Compare Biohit Oyj B with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 51 · Above median
Fair Value upside +16% · Top 25%
Profitability
Return on equity (TTM) 20% · Top 25%
Return on assets 11% · Top 25%
Net margin (TTM) 17% · Top 25%
Operating margin (TTM) 22% · Top 25%
Growth and dividend
Revenue growth 21% · Top 25%
Balance sheet
Debt / equity 0.00× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 12.9× · Cheapest 25%
P/B 3.11× · Pricier than median
P/S (TTM) 2.95× · Pricier than median
EV/EBITDA 13.7× · Cheaper than median
PEG 7.04× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)55 · sector 10
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)81 · sector 7
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.07 $74.79 −26%
Stryker Corporation SYK $273.40 $300.74 +10%
Medtronic plc MDT $89.30 $65.57 −27%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biohit Oyj B · Fair Value
€2.71 +14%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Biohit Oyj B Fair Value". https://www.fairvalue-calculator.com/stock/BIOBV

Frequently asked questions

Is Biohit Oyj B (BIOBV) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €2.71 versus a price of €2.33, about +16% upside (undervalued).
What is the fair value of BIOBV?
Our model-based fair value for Biohit Oyj B is €2.71 (as of Sep 23, 2026), built from audited fundamentals. The current price: €2.33.
What is the quality score of BIOBV?
Biohit Oyj B has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biohit Oyj B (BIOBV)?
Our model-based price target is the fair value of €2.71 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario €2.20, optimistic scenario €3.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Biohit Oyj B stock forecast for 2026?
Our models put fair value at €2.71, about +16% upside versus a price of €2.33 (undervalued). Cautious scenario €2.20, optimistic scenario €3.30. The calculation is refreshed regularly with new filings.
What is the revenue of Biohit Oyj B (BIOBV)?
Biohit Oyj B reported trailing-twelve-month revenue of about €15.7M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Biohit Oyj B (BIOBV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biohit Oyj B it is €2.71 per share (as of Sep 23, 2026), against a price of €2.33. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Biohit Oyj B stock overvalued or undervalued in 2026?
As of Sep 23, 2026, BIOBV trades below its calculated fair value: price €2.33, fair value €2.71, a gap of about +16% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOBV?
No. The price is what the market pays today (€2.33); the fair value is what the company's own numbers justify (€2.71). For Biohit Oyj B the two are €0.3800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biohit Oyj B worth?
The market values Biohit Oyj B at about €40.8M (market capitalisation, as of Sep 23, 2026). Per share that is €2.33; our models calculate a fair value of €2.71 per share.
What do the bullish and bearish scenarios say about BIOBV?
Our models span a range for Biohit Oyj B: cautious scenario €2.20, base €2.71, optimistic €3.30 per share (as of Sep 23, 2026, price €2.33). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BIOBV?
Biohit Oyj B trades at a price-to-earnings ratio of 12.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €2.71 is built from several models across several years. Other multiples: PEG 7.0, P/B 3.1, P/S 2.9, EV/EBITDA 13.7.
What is the PEG ratio of BIOBV?
The PEG ratio of Biohit Oyj B is 7.04 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Biohit Oyj B (BIOBV)?
Balance-sheet figures for Biohit Oyj B (as of Sep 23, 2026): return on equity 20.2%, debt of 0.00 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is BIOBV from its 52-week high?
Biohit Oyj B trades at €2.33, about 37% below its 52-week high of €3.70 and 5% above the low of €2.21 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €2.71 is for.
Which stocks are comparable to Biohit Oyj B?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biohit Oyj B stock attractive at the current price?
The data as of Sep 23, 2026: price €2.33, calculated fair value €2.71 (+16%), Quality Score 51/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOBV calculated?
We run Biohit Oyj B through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €2.71, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Biohit Oyj B currently trades 16 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biohit Oyj B (BIOBV)?
The closing price on Sep 24, 2026 was €2.33. Our model-based fair value is €2.71, about +16% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biohit Oyj B right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Biohit Oyj B

How large is the market capitalisation of Biohit Oyj B (BIOBV)?
The market capitalisation of Biohit Oyj B is €40.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biohit Oyj B (BIOBV)?
The price-to-sales ratio of Biohit Oyj B is 2.22 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biohit Oyj B (BIOBV)?
Earnings per share at Biohit Oyj B are €0.1802 (price ÷ EPS = P/E 12.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biohit Oyj B (BIOBV)?
The net margin of Biohit Oyj B is 17.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biohit Oyj B (BIOBV)?
The return on equity (ROE) of Biohit Oyj B is 20.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biohit Oyj B (BIOBV)?
On an EBIT basis the return on assets of Biohit Oyj B is 8.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biohit Oyj B (BIOBV)?
The operating margin of Biohit Oyj B is 22.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biohit Oyj B (BIOBV)?
Revenue at Biohit Oyj B is growing +21.1% versus a year earlier (3y avg +12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biohit Oyj B (BIOBV)?
Earnings per share at Biohit Oyj B are growing +32.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Biohit Oyj B (BIOBV) generate?
The free cash flow of Biohit Oyj B is −€1.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Biohit Oyj B (BIOBV) hold?
Biohit Oyj B holds more cash than debt, €1.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Biohit Oyj B in the live analysis

One click puts Biohit Oyj B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.